

Resource Summary Report

Generated by [RRID](#) on Aug 16, 2026

Medicines for Malaria Venture

RRID:SCR_008603

Type: Tool

Proper Citation

Medicines for Malaria Venture (RRID:SCR_008603)

Resource Information

URL: <http://www.mmv.org/>

Proper Citation: Medicines for Malaria Venture (RRID:SCR_008603)

Description: MMV, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. Our mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. Sponsors/Donors: -Bill and Melinda Gates Foundation -CRIMALDDI -ExxonMobil -Irish Aid -National Institutes of Health -Netherlands Ministry of Foreign Affairs -Rockefeller Foundation (former donor) - Secretaria de Estado de Cooperacin Internacional (Spanish Agency for International Cooperation) -Swiss Agency for Development and Cooperation -UK Department for International Development -USAID -Wellcome Trust -World Bank -World Health Organization

Abbreviations: MMV

Synonyms: MMV

Resource Type: nonprofit organization

Resource Name: Medicines for Malaria Venture

Resource ID: SCR_008603

Alternate IDs: nif-0000-31938, Wikidata: Q6806774, Crossref funder ID: 501100004167, grid.452605.0, ISNI: 0000 0004 0432 5267

Alternate URLs: <https://ror.org/00p9jf779>

Record Creation Time: 20220129T080248+0000

Ratings and Alerts

No rating or validation information has been found for Medicines for Malaria Venture.

No alerts have been found for Medicines for Malaria Venture.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 91 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Taki AC, et al. (2026) High-throughput phenotypic screening of Medicines for Malaria Venture's Hit Generation Library 1 identifies new nematocidal chemotypes. International journal for parasitology. Drugs and drug resistance, 30, 100638.

Vo TK, et al. (2026) Trafficking and organization of cyst wall components into a robust biphasic structure in Entamoeba. PLoS pathogens, 22(2), e1013940.

Barnes CB, et al. (2026) Unpacking boxes: identification of novel inhibitors of malaria parasite invasion. International journal for parasitology. Drugs and drug resistance, 31, 100647.

Harding SD, et al. (2026) The IUPHAR/BPS Guide to PHARMACOLOGY in 2026. Nucleic acids research, 54(D1), D1446.

Braunack-Mayer L, et al. (2026) Combining seasonal malaria chemoprevention with novel therapeutics for malaria prevention: a mathematical modelling study. PLoS computational biology, 22(2), e1014021.

Akazue PI, et al. (2026) Phenotypic profiling of Pathogen Box compounds MMV667494 and MMV028694 in bloodstream-form Trypanosoma brucei brucei. Experimental biology and medicine (Maywood, N.J.), 251, 10979.

Chepkirui M, et al. (2025) Missed opportunities for digital health data use in healthcare decision-making: A cross-sectional digital health landscape assessment in Homa Bay county, Kenya. PLOS digital health, 4(6), e0000870.

Gawriljuk VO, et al. (2025) Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors. ACS omega, 10(37), 42711.

Dawood WA, et al. (2025) Antiplasmodial activity of pentyloxyamide-based histone deacetylase inhibitors against Plasmodium falciparum parasites. International journal for

parasitology. Drugs and drug resistance, 29, 100608.

Harding SD, et al. (2024) The IUPHAR/BPS Guide to PHARMACOLOGY in 2024. Nucleic acids research, 52(D1), D1438.

Naude M, et al. (2024) Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials. Nature communications, 15(1), 9896.

Greyling N, et al. (2024) Genetic complexity alters drug susceptibility of asexual and gametocyte stages of *Plasmodium falciparum* to antimalarial candidates. Antimicrobial agents and chemotherapy, 68(3), e0129123.

Cherkaoui-Rbati MH, et al. (2023) A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria. CPT: pharmacometrics & systems pharmacology, 12(1), 50.

do Valle Moreira T, et al. (2023) Screening the Pathogen Box to Discover and Characterize New Cruzain and TbrCatL Inhibitors. Pathogens (Basel, Switzerland), 12(2).

Dembele L, et al. (2023) Ethiopian *Plasmodium vivax* hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs. BMC infectious diseases, 23(1), 405.

Siqueira-Neto JL, et al. (2023) Antimalarial drug discovery: progress and approaches. Nature reviews. Drug discovery, 22(10), 807.

Goethals O, et al. (2023) A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships. Antiviral research, 210, 105495.

Moyo P, et al. (2023) Leveraging off higher plant phylogenetic insights for antiplasmodial drug discovery. Natural products and bioprospecting, 13(1), 35.

Probst L, et al. (2023) Generation and Characterization of an Influenza D Reporter Virus. Viruses, 15(12).

Dos Reis TF, et al. (2023) A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi. Nature communications, 14(1), 2052.